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We report the experience of 41 patients (21 males, 20 females;
mean age, 8.1 years; range, 0.2–22.6 years) treated with RIC and
allogeneic HSCT. Diagnoses consisted of malignancies in 24 (20
hematologic and 4 refractory neuroblastoma) and nonmalignant
disorders in 17: immunodeﬁciencies in 6, metabolic disorders in 5,
hemoglobinopathies in 4, and aplastic anemia in 2. Twelve patients
had prior HSCT (7 autologous and 5 allogeneic). Recipient’s racial
origins included 22 Caucasian, 10 Hispanic, 7 African American,
and 2 Asian. A standardized RIC regimen comprised of ﬂudara-
bine, 30 mg/m2 for 6 days (days 10 to 5), followed by intrave-
nous busulfan, 0.8–1 mg/kg for 8 doses or targeted busulfan at
AUC 4000 mmol/min for 2 doses (days 5 and 4) and equine
ATG, 40 mg/kg or rabbit ATG, 2 mg/kg for 4 days (days 4
through1) was administered. Graft-versus-host disease (GVHD)
prophylaxis was cyclosporin A (CsA) alone in 19 patients and CsA
and mycophenolate mofetil in 22 patients. Growth factor support
was not used. Stem cell sources included 27 unrelated donors and
14 related donors; 34 of 41 sources were peripheral blood stem
cells. We also assessed engraftment by determining the number of
days required to achieve  50% and  95% donor chimerism
(Do-chim) by VNTR in total leukocyte and T-lymphocyte (CD3)
populations.
The median cell doses infused were 5.8  108 MNC/kg and 2 
106 CD34 cells/kg. Seven of 41 patients failed to engraft, and 3
patients were not evaluable due to early deaths from toxicity (in 2)
or relapse (in 1). Four of 16 evaluable patients with nonmalignant
disorders failed to engraft versus 3 of 22 with malignancies. Pa-
tients failing to engraft were younger (median age, 6.3 vs 8.8 years)
and weighed less (median weight, 18 vs 27 kg), but received lower
cell infusion doses (3.9 vs 5.9  108 MNC/kg; P  .05). The
median time to a postnadir ANC of 500/L was 16.5 days, and
unsupported platelet count  20,000/L was 19 days. Data shown
in the table indicate trends for more rapid achievement of Do-chim
in patients treated for malignancy. Also, within the 14 malignancy
patients, those with clinically signiﬁcant acute (II-IV) and/or ex-
tensive chronic GVHD demonstrated faster Do-chim.
These measures of engraftment may provide a reproducible com-
parison of engraftment in the setting of RIC and resulting mixed
chimeric states. These parameters may provide insight to promote
engraftment or to balance a desired graft-versus-tumor effect in
patients with malignancies versus limitation of GVHD for patients
with no beneﬁt from an excessive alloimmune response.
Table 1. Median Number of Days to Achieve Donor-Chimerism
Leukocyte
Do-chim
50
Leukocyte
Do-chim
95
Lymphocyte
Do-chim
50
Lymphocyte
Do-chim
95
Evaluable Pts
(n  26) 18 26 25 33
Non-malignant
Disorders
(n  11) 19 53 26 82.5
Malignancy Pts
(n  15) 13 25 21 27
Malignancy &
GVHD
(n  7) 13 17 20 19
Malignancy
without
GVHD
(n  8) 16 32.5 26.5 39
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Allogeneic hematopoietic stem cell transplantation (HSCT) of-
fers a high chance for cure in patients with nonmalignant disorders.
However, acute and late complications as consequence of the
conditioning regimen and severe immunosuppression are still a
matter of concern. Only few studies speciﬁcally focused on the risk
for treatment-related mortality (TRM) in children. To evaluate
factors inﬂuencing the outcome after HSCT we retrospectively
analyzed 342 children given allogeneic SCT. The median age was
8.7 years; 230 patients suffered from hematologic malignancies,
112 from nonmalignant disorders (SAA, immunodeﬁciency syn-
dromes, metabolic disorders, thalassemia, sickle cell disease, he-
mophagocytic syndromes). The 360-day TRM (in nonmalignant
diseases, 0.17) was inﬂuenced by donor type (HLA-identical sibling
donors vs phenotypically matched family or unrelated donors vs
mismatched donors), time of SCT (before and after 1997), stage of
disease (early vs advanced), conditioning regimen (myeloablative vs
reduced), graft manipulation (T-cell depletion vs no TCD) and
history of severe organ dysfunction and/or infections. Most fre-
quent causes of death were organ toxicity, acute GvHD, and
infections. The following factors were independent risk factors for
TRM: graft failure, resistant disease, CMV IgG-negative donors
for CMV IgG-positive patients, HLA mismatch  2 alleles, TCD
graft, and history of severe toxicity and/or infection. The pattern of
severe adverse events changed over time. In the ﬁrst years, GvHD
was the most frequent life-threatening complication, followed by
toxicity and infections. More recently, viral infections are the
major reason for TRM, particularly in patients transplanted from
HLA-mismatched donors given T-cell–depleted grafts. The cu-
mulative incidence of TRM in patients transplanted after 1997 was
0.06 from matched sibling donors, 0.14 from unrelated donors, and
0.27 and from HLA-mismatched donors. Factors associated with
improved survival incuded the quality of HLA typing (high-reso-
lution techniques in HLA class I and II), reduced intensity condi-
tioning, monitoring and preemptive treatment (pharmacologic and
virus-speciﬁc cell support) of viral infections, and experience (cen-
ter size  10 allogeneic SCTs vs  10 per year). We conclude that
today, the risk for TRM especially in children with nonmalignant
diseases undergoing HSCT could be reduced by multidisciplinary
approaches focusing the enhancement of immunologic reconstitution.
246
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Umbilical cord blood transplantation (UCBT) favorably alters
the natural history of young pediatric patients with Hurler syn-
drome (MPS I). We asked whether it would also be effective for
patients with Sanﬁlippo syndrome (MPS III). Patients with San-
ﬁlippo syndrome have less somatic and more CNS disease than
patients with other MPS syndromes. They are typically diagnosed
between 3 and 5 years of age. Without treatment, they develop
severe neurologic dysfunction, deafness, inability to speak or am-
bulate, and severely autistic behaviors. Death occurs between 10
and 13 years of age. Currently, allogeneic stem cell transplantation
(SCT) is the only way to deliver healthy enzyme to the brain. We
hypothesized that children with Sanﬁlippo syndrome would beneﬁt
from UCBT, particularly if it was performed early in the course of
the disease. Between February 2001 and April 2004, 12 children
(age 10–59 months, 75% male, 100% Caucasian) underwent
UCBT. All were prepared for transplantation with myeloablative
chemotherapy (busulfan/cyclophosphamide/ATG), and all re-
ceived prophylaxis against GvHD with cyclosporine and steroids.
They were transplanted with unrelated donor UCB grafts match-
ing at 6/6 (n  1), 5/6 (n  7), and 4/6 (n  4) HLA loci,
containing a median of 6.5 107 nucleated cells/kg and 1.42 105
CD34 cells/kg. Donor cell engraftment (ANC 500/L) occurred
in 9 of 12 children in a median of 24 days. Platelet engraftment
(platelet count 50K/L untransfused) occurred in 7 of 12 children
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